IN VITRO METHOD FOR THE DIAGNOSIS AND/OR PROGNOSIS OF MALIGNANT MELANOMA

Technology for Licensing

Keywords:

SNP, expression patterns, single nucleotide polymorphism, melanoma, malignant melanoma, biomarkers, CLPTM1L, TYR, precision medicine.

Description:

Malignant melanoma, with a growing prevalence in recent years, is skin cancer's most aggressive form, representing the leading cause of death from skin diseases.

The intratumoral heterogeneity and the complexity of the current status of germline mutations in this type of cancer make it complex to design therapeutic strategies. Thereby, there is a medical need to find reliable biomarkers for an early diagnosis and prognosis of MM, which will facilitate adequate monitoring of the disease, a correct choice of treatment and the control of its subsequent response.

In this sense, the present invention proposes eight risk SNPs are related to melanoma, proposing them for use as biomarkers and gene signatures of this condition, aiding earlier identification and thus shortening the time to initiation of treatment.

These promising markers form the basis of this *in vitro* method that allows a diagnosis of MM in patients at risk or with signs of suffering it from a simple biological sample. As well, it assesses whether patients who are being treated respond to such therapy. Thus, the presence of at least one of these SNPs: CLPTM1L (rs401681), LOC107987026 (rs1335510), TYRP1 (rs2733832), MTAP (rs7023329), TYR (rs1126809), MX2 (rs45430), CTXND2 (rs7412746) and PARP1 (rs3219090); or a high expression level in the TYRP1 and TYR genes are considered indications that the individual has MM, has a poor prognosis or is responding poorly to treatment.

Therefore, this method is an aid to improve precision medicine for MM patients and their closest relatives.

Actuación en el marco de los Proyectos R-PDTC-2018 y PAIDI AT17_6096_OTRI UGR







A group of single nucleotide polymorphisms (SNPs) related to the risk and aggressiveness of malignant melanoma (MM) has been identified. Thus, an *in vitro* method based on these biomarkers identification is proposed for diagnosis and/or prognosis of malignant melanoma and determine whether these patients respond adequately to treatment.

In the same way, it has been proved with *in vitro* and *in silico* expression assays, which these SNPs for risk and aggressiveness of MM are reinforced.

Advantages and Benefits

- Early diagnosis of MM and its prognosis
- Assessment of response to treatment in patients diagnosed with MM
- >>> Improved precision medicine

It helps to be more accurate in diagnosing melanoma patients and their closest relatives

- >>> The biological sample to be analyzed is easily accessible: skin tissue, saliva, blood, urine, serum or plasma
- >>> No specific equipment is required

SNPs genotyping and the quantification of the expression levels of these biomarkers is carried out by PCR and/or qPCR

Simple method

Scheme of the in vitro method of this invention



Patent status:

Patent application:EP21382617.5Priority date:08/07/2021

Contact:

Oficina de Transferencia de Resultados de Investigación (OTRI) - Universidad de Granada

Lucas Montes Pérez <u>lumontes@ugr.es</u> (+34) 958 249 390